Comments
Loading...

Biogen Analyst Ratings

BIIBNASDAQ
Logo brought to you by Benzinga Data
$126.54
-0.02-0.02%
At close: -
$126.54
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$342.00
Lowest Price Target1
$115.00
Consensus Price Target1
$202.38

Biogen Analyst Ratings and Price Targets | NASDAQ:BIIB | Benzinga

Biogen Inc has a consensus price target of $202.38 based on the ratings of 30 analysts. The high is $342 issued by HSBC on May 3, 2024. The low is $115 issued by Piper Sandler on June 12, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Wedbush, and Mizuho on June 12, 2025, June 12, 2025, and May 7, 2025, respectively. With an average price target of $135 between Piper Sandler, Wedbush, and Mizuho, there's an implied 6.69% upside for Biogen Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
5
5
Feb
3
2
Apr
5
1
May
2
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Wedbush
Mizuho
JP Morgan
RBC Capital

1calculated from analyst ratings

Analyst Ratings for Biogen

Buy NowGet Alert
06/12/2025Buy Now-9.12%Piper Sandler
David Amsellem74%
$115 → $115ReiteratesNeutral → NeutralGet Alert
06/12/2025Buy Now-4.38%Wedbush
Laura Chico51%
$121 → $121ReiteratesNeutral → NeutralGet Alert
06/12/2025Buy NowNeedham
Ami Fadia60%
ReiteratesHold → HoldGet Alert
05/07/2025Buy Now33.55%Mizuho
Salim Syed44%
$207 → $169MaintainsOutperformGet Alert
05/05/2025Buy Now38.3%JP Morgan
Chris Schott59%
$185 → $175MaintainsNeutralGet Alert
05/02/2025Buy Now62%RBC Capital
Brian Abrahams49%
$217 → $205MaintainsOutperformGet Alert
05/02/2025Buy Now73.86%Canaccord Genuity
Sumant Kulkarni43%
$265 → $220MaintainsBuyGet Alert
05/02/2025Buy Now47.78%HC Wainwright & Co.
Andrew Fein61%
$241 → $187MaintainsBuyGet Alert
05/02/2025Buy Now101.52%Baird
Brian Skorney59%
$300 → $255MaintainsOutperformGet Alert
05/02/2025Buy NowNeedham
Ami Fadia60%
ReiteratesHold → HoldGet Alert
04/29/2025Buy Now57.26%Truist Securities
Srikripa Devarakonda44%
$210 → $199MaintainsBuyGet Alert
04/29/2025Buy Now-9.12%Piper Sandler
Christopher Raymond55%
$135 → $115MaintainsNeutralGet Alert
04/25/2025Buy NowNeedham
Ami Fadia60%
ReiteratesHold → HoldGet Alert
04/23/2025Buy Now55.68%Goldman Sachs
Salveen Richter52%
$219 → $197MaintainsBuyGet Alert
04/22/2025Buy Now77.81%RBC Capital
Brian Abrahams49%
$221 → $225MaintainsOutperformGet Alert
04/16/2025Buy NowNeedham
Ami Fadia60%
ReiteratesHold → HoldGet Alert
04/09/2025Buy Now20.12%Morgan Stanley
Matthew Harrison61%
$157 → $152MaintainsEqual-WeightGet Alert
04/04/2025Buy NowArgus Research
Jasper Hellweg68%
DowngradeBuy → HoldGet Alert
02/18/2025Buy Now6.69%Piper Sandler
Christopher Raymond55%
$138 → $135ReiteratesNeutral → NeutralGet Alert
02/13/2025Buy Now77.02%Scotiabank
George Farmer43%
$244 → $224MaintainsSector OutperformGet Alert
02/13/2025Buy Now9.85%BMO Capital
Evan Seigerman63%
$156 → $139MaintainsMarket PerformGet Alert
02/13/2025Buy Now24.07%Morgan Stanley
Matthew Harrison61%
$192 → $157MaintainsEqual-WeightGet Alert
02/13/2025Buy Now93.61%Goldman Sachs
Salveen Richter52%
$281 → $245MaintainsBuyGet Alert
02/13/2025Buy Now77.81%RBC Capital
Brian Abrahams49%
$231 → $225MaintainsOutperformGet Alert
02/13/2025Buy Now14.59%Citigroup
Geoff Meacham62%
$160 → $145MaintainsNeutralGet Alert
02/13/2025Buy Now10.64%Wells Fargo
Mohit Bansal68%
$165 → $140MaintainsEqual-WeightGet Alert
02/13/2025Buy Now90.45%HC Wainwright & Co.
Andrew Fein61%
$300 → $241MaintainsBuyGet Alert
02/13/2025Buy Now65.96%Truist Securities
Srikripa Devarakonda44%
$220 → $210MaintainsBuyGet Alert
02/13/2025Buy Now109.42%Canaccord Genuity
Sumant Kulkarni43%
$298 → $265MaintainsBuyGet Alert
02/13/2025Buy NowNeedham
Ami Fadia60%
ReiteratesHold → HoldGet Alert
01/28/2025Buy Now26.44%Citigroup
Geoff Meacham62%
$190 → $160MaintainsNeutralGet Alert
01/10/2025Buy Now30.39%Wells Fargo
Mohit Bansal68%
$190 → $165MaintainsEqual-WeightGet Alert
01/08/2025Buy Now73.86%Truist Securities
Srikripa Devarakonda44%
$302 → $220MaintainsBuyGet Alert
01/02/2025Buy Now9.06%Piper Sandler
Christopher Raymond55%
$315 → $138DowngradeOverweight → NeutralGet Alert
12/20/2024Buy Now29.6%BMO Capital
Evan Seigerman63%
$230 → $164DowngradeOutperform → Market PerformGet Alert
12/10/2024Buy Now40.67%B of A Securities
Tim Anderson66%
→ $178Reinstates → NeutralGet Alert
12/09/2024Buy Now42.25%Jefferies
Michael Yee56%
$250 → $180DowngradeBuy → HoldGet Alert
11/21/2024Buy Now63.58%Mizuho
Salim Syed44%
$251 → $207MaintainsOutperformGet Alert
11/18/2024Buy Now113.37%Needham
Ami Fadia60%
$270 → $270DowngradeBuy → HoldGet Alert
11/15/2024Buy Now137.08%Baird
Brian Skorney59%
$294 → $300MaintainsOutperformGet Alert
11/15/2024Buy NowWolfe Research
Alexandria Hammond53%
Initiates → Peer PerformGet Alert
11/14/2024Buy Now50.15%Citigroup
Geoff Meacham62%
→ $190Initiates → NeutralGet Alert
11/04/2024Buy Now65.96%JP Morgan
Chris Schott59%
$220 → $210MaintainsNeutralGet Alert
10/31/2024Buy Now101.52%Oppenheimer
Jay Olson60%
$270 → $255MaintainsOutperformGet Alert
10/31/2024Buy Now42.25%Barclays
Carter Gould55%
$190 → $180MaintainsEqual-WeightGet Alert
10/31/2024Buy Now117.32%TD Cowen
Phil Nadeau66%
$300 → $275MaintainsBuyGet Alert
10/31/2024Buy Now137.08%HC Wainwright & Co.
Andrew Fein61%
$300 → $300ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now113.37%Needham
Ami Fadia60%
$270 → $270ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now61.21%Morgan Stanley
Matthew Harrison61%
$285 → $204DowngradeOverweight → Equal-WeightGet Alert
10/30/2024Buy Now113.37%Needham
Ami Fadia60%
$270 → $270ReiteratesBuy → BuyGet Alert
10/17/2024Buy Now81.76%BMO Capital
Evan Seigerman63%
$260 → $230MaintainsOutperformGet Alert
10/10/2024Buy NowRaymond James
Danielle Brill42%
Reinstates → Market PerformGet Alert
10/04/2024Buy Now112.58%RBC Capital
Brian Abrahams49%
$292 → $269MaintainsOutperformGet Alert
10/03/2024Buy Now59.63%UBS
Colin Bristow39%
$234 → $202MaintainsNeutralGet Alert
09/24/2024Buy Now125.23%Needham
Ami Fadia60%
$285 → $285ReiteratesBuy → BuyGet Alert
09/23/2024Buy Now62%Wedbush
Laura Chico51%
$210 → $205MaintainsNeutralGet Alert
09/19/2024Buy Now130.76%RBC Capital
Brian Abrahams49%
$292 → $292ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now130.76%Cantor Fitzgerald
Eric Schmidt32%
$292 → $292ReiteratesOverweight → OverweightGet Alert
09/04/2024Buy Now125.23%Needham
Ami Fadia60%
$285 → $285ReiteratesBuy → BuyGet Alert
08/19/2024Buy Now125.23%Needham
Ami Fadia60%
$285 → $285ReiteratesBuy → BuyGet Alert
08/06/2024Buy Now98.36%Mizuho
Salim Syed44%
$277 → $251MaintainsOutperformGet Alert
08/05/2024Buy Now138.66%Truist Securities
Srikripa Devarakonda44%
$340 → $302ReiteratesBuy → BuyGet Alert
08/05/2024Buy Now125.23%Needham
Ami Fadia60%
$288 → $285MaintainsBuyGet Alert
08/02/2024Buy Now130.76%RBC Capital
Brian Abrahams49%
$282 → $292MaintainsOutperformGet Alert
08/02/2024Buy Now77.81%Wells Fargo
Mohit Bansal68%
$240 → $225MaintainsEqual-WeightGet Alert
08/02/2024Buy Now92.82%Scotiabank
George Farmer43%
$275 → $244MaintainsSector OutperformGet Alert
08/02/2024Buy Now50.15%Barclays
Carter Gould55%
$200 → $190MaintainsEqual-WeightGet Alert
08/02/2024Buy Now65.96%Wedbush
Laura Chico51%
$215 → $210MaintainsNeutralGet Alert
08/01/2024Buy Now127.6%Needham
Ami Fadia60%
$288 → $288ReiteratesBuy → BuyGet Alert
07/29/2024Buy Now132.34%Baird
Brian Skorney59%
$316 → $294MaintainsOutperformGet Alert
07/26/2024Buy Now132.34%Needham
Ami Fadia60%
$294 → $294ReiteratesBuy → BuyGet Alert
07/12/2024Buy Now147.35%Piper Sandler
Christopher Raymond55%
$335 → $313MaintainsOverweightGet Alert
06/28/2024Buy Now132.34%Needham
Ami Fadia60%
$294 → $294ReiteratesBuy → BuyGet Alert
06/27/2024Buy Now150.51%RBC Capital
Brian Abrahams49%
$317 → $317ReiteratesOutperform → OutperformGet Alert
06/26/2024Buy Now150.51%RBC Capital
Brian Abrahams49%
$317 → $317ReiteratesOutperform → OutperformGet Alert
06/05/2024Buy Now150.51%RBC Capital
Brian Abrahams49%
$317 → $317ReiteratesOutperform → OutperformGet Alert
05/29/2024Buy Now150.51%RBC Capital
Brian Abrahams49%
→ $317ReiteratesOutperform → OutperformGet Alert
05/23/2024Buy Now137.08%HC Wainwright & Co.
Andrew Fein61%
$300 → $300ReiteratesBuy → BuyGet Alert
05/22/2024Buy Now132.34%Needham
Ami Fadia60%
$294 → $294ReiteratesBuy → BuyGet Alert
05/16/2024Buy Now168.69%Truist Securities
Robyn Karnauskas54%
$340 → $340MaintainsBuyGet Alert
05/03/2024Buy Now170.27%HSBC
Morten Herholdt36%
$339 → $342MaintainsBuyGet Alert
04/29/2024Buy Now113.37%Oppenheimer
Jay Olson60%
$270 → $270MaintainsOutperformGet Alert
04/25/2024Buy Now132.34%Needham
Ami Fadia60%
$294 → $294ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now58.05%Barclays
Carter Gould55%
$215 → $200MaintainsEqual-WeightGet Alert
04/25/2024Buy Now69.91%Wedbush
Laura Chico51%
$213 → $215MaintainsNeutralGet Alert
04/25/2024Buy Now137.08%HC Wainwright & Co.
Andrew Fein61%
$325 → $300MaintainsBuyGet Alert
04/24/2024Buy Now132.34%Needham
Ami Fadia60%
$294 → $294ReiteratesBuy → BuyGet Alert
04/19/2024Buy Now113.37%Oppenheimer
Jay Olson60%
$290 → $270MaintainsOutperformGet Alert
04/17/2024Buy Now69.12%UBS
Colin Bristow39%
$250 → $214MaintainsNeutralGet Alert
04/17/2024Buy Now68.33%Wedbush
Laura Chico51%
$245 → $213MaintainsNeutralGet Alert
04/12/2024Buy Now105.47%B of A Securities
Geoff Meacham62%
$280 → $260MaintainsNeutralGet Alert
04/11/2024Buy Now89.66%JP Morgan
Chris Schott59%
$270 → $240MaintainsNeutralGet Alert
04/04/2024Buy Now69.91%Barclays
Carter Gould55%
$230 → $215MaintainsEqual-WeightGet Alert
03/25/2024Buy Now168.69%Truist Securities
Robyn Karnauskas54%
→ $340ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now187.66%RBC Capital
Brian Abrahams49%
$364 → $364ReiteratesOutperform → OutperformGet Alert
02/22/2024Buy Now118.9%Mizuho
Salim Syed44%
$355 → $277MaintainsBuyGet Alert
02/20/2024Buy Now145.77%Cantor Fitzgerald
Eric Schmidt32%
$311 → $311ReiteratesOverweight → OverweightGet Alert
02/20/2024Buy Now141.03%Canaccord Genuity
Sumant Kulkarni43%
$310 → $305MaintainsBuyGet Alert
02/16/2024Buy Now97.57%UBS
Colin Bristow39%
$276 → $250MaintainsNeutralGet Alert
02/14/2024Buy Now156.84%HC Wainwright & Co.
Andrew Fein61%
$325 → $325ReiteratesBuy → BuyGet Alert

FAQ

Q

What is the target price for Biogen (BIIB) stock?

A

The latest price target for Biogen (NASDAQ:BIIB) was reported by Piper Sandler on June 12, 2025. The analyst firm set a price target for $115.00 expecting BIIB to fall to within 12 months (a possible -9.12% downside). 75 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Biogen (BIIB)?

A

The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Piper Sandler, and Biogen reiterated their neutral rating.

Q

When was the last upgrade for Biogen (BIIB)?

A

There is no last upgrade for Biogen

Q

When was the last downgrade for Biogen (BIIB)?

A

The last downgrade for Biogen Inc happened on April 4, 2025 when Argus Research changed their price target from N/A to N/A for Biogen Inc.

Q

When is the next analyst rating going to be posted or updated for Biogen (BIIB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on June 12, 2025 so you should expect the next rating to be made available sometime around June 12, 2026.

Q

Is the Analyst Rating Biogen (BIIB) correct?

A

While ratings are subjective and will change, the latest Biogen (BIIB) rating was a reiterated with a price target of $115.00 to $115.00. The current price Biogen (BIIB) is trading at is $126.54, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch